Document Detail

Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.
MedLine Citation:
PMID:  19891686     Owner:  NLM     Status:  MEDLINE    
Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment.
Antonio Giovanni Richetta; Elisa Maiani; Valentina Carlomagno; Valentina Carboni; Carlo Mattozzi; Simona Giancristoforo; Stefano Calvieri
Related Documents :
10921396 - Firstline treatment for hepatitis c: combination interferon/ribavirin versus interferon...
18327466 - Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients in...
12897906 - Hepatis c virus genotype 4.
15249636 - Improvement of a cidp associated with hepatitis c virus infection using antiviral therapy.
17438666 - Pediatric hiv infection: immune and viral evaluation.
11240656 - Ovarian carcinoma, pericardial metastasis and human immunodeficiency virus infection.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Dermatologic therapy     Volume:  22 Suppl 1     ISSN:  1529-8019     ISO Abbreviation:  Dermatol Ther     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-06     Completed Date:  2010-02-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9700070     Medline TA:  Dermatol Ther     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  S16-8     Citation Subset:  IM    
Department of Cutaneous and Venereal Diseases and Plastic Surgery, Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antiviral Agents / administration & dosage
Dermatitis, Exfoliative / drug therapy*,  etiology
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy*
Interferon-alpha / administration & dosage
Middle Aged
Polyethylene Glycols / administration & dosage
Psoriasis / drug therapy*,  etiology
Recombinant Proteins
Ribavirin / administration & dosage
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/interferon alfa-2a; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cutaneous lesions as initial signs of interferon alpha-induced sarcoidosis: report of three new case...
Next Document:  Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin:...